Omarigliptin
- Generic Name
- Omarigliptin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20F2N4O3S
- CAS Number
- 1226781-44-7
- Unique Ingredient Identifier
- CVP59Q4JE1
- Background
Omarigliptin has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Chronic Renal Insufficiency.
- Indication
用于治疗2型糖尿病。
- Associated Conditions
- -
- Associated Therapies
- -
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
- Target Recruit Count
- 938
- Registration Number
- NCT06449235
- Locations
- 🇧🇩
BIRDEM General Hospital, Dhaka, Bangladesh
Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 184
- Registration Number
- NCT02906709
A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 65
- Registration Number
- NCT01863667
Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 642
- Registration Number
- NCT01841697
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-03-20
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 203
- Registration Number
- NCT01814748
A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT01767688
A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 402
- Registration Number
- NCT01755156
A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 329
- Registration Number
- NCT01717313
Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 307
- Registration Number
- NCT01704261
Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 414
- Registration Number
- NCT01703221
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath